FDA Approves Ixifi, a Remicade Biosimilar, for Ankylosing Spondylitis, Other Indications
The U.S. Food and Drug Administration (FDA) has approved Pfizer’s Ixifi (infliximab-qbtx), a biosimilar to Janssen Biotech’s Remicade, for all indications approved for the reference product, including ankylosing spondylitis. Like Remicade, Ixifi is a chimeric human-murine monoclonal antibody against tumor necrosis factor (TNF). TNF is involved in…